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Acute myocardial infarction (AMI) is defined as myocardial cell death caused by 
prolonged myocardial ischemia. Although advances in both acute and secondary 
prevention treatment in recent years have improved the prognosis of the disease, it 
continues to have a great impact on society, as 14% of individuals with AMI will die 
because of it in the following year. First, this project seeks to contextualize, through 
epidemiological studies, the relevance of type 1 AMI worldwide, as well as the acute 
treatment of the disease. Finally, it delves into the pathophysiology involved and focuses 
on prevention. Accumulation of low density lipoproteins (LDL) in the arterial wall is one 
of the major risk factors for developing atherosclerosis, the main trigger for type 1 AMI. 
Statins are currently established as the reference treatment for AMI prevention, both in 
monotherapy and in combination with other lipid-lowering drugs. Combined therapies 
have shown to induce major reductions in cardiovascular risk, but research must be 
continued to improve outcomes. Statins have traditionally been used together with 
cholesterol absorption inhibitors, bile acid sequestrants and fibrates. A new lipid-
lowering drug family, monoclonal antibodies inhibiting PCSK9 proteins, has been 
developed recently, showing promising results for the disease prevention, awaiting 
further safety and efficiency studies. 
 
Resum 
L’infart agut de miocardi (AMI) es defineix com la mort del miocardi causada per una 
isquèmia prolongada. Tot i que els avenços en el tractament tant agut com de prevenció 
secundària dels últims anys han millorat la prognosi de la malaltia, aquesta segueix 
tenint un gran impacte en la societat, ja que el 14% dels individus que pateixin un AMI 
en moriran com a conseqüència abans d'un any. En primer lloc, aquest treball busca 
contextualitzar, mitjançant estudis epidemiològics, la rellevància global de l’AMI tipus 1 
així com el tractament agut de la malaltia. Finalment, aprofundeix en la fisiopatologia 
involucrada per després centrar-se en la prevenció. L’acumulació de lipoproteïnes de 
baixa densitat en la paret arterial és un dels principals factors de risc per a desenvolupar 
aterosclerosi, el desencadenant principal de l’AMI tipus 1. Actualment les estatines 




monoteràpia com en teràpia combinada amb altres fàrmacs hipolipemiants. Les teràpies 
combinades han demostrat induir majors reduccions del risc d’esdeveniments 
cardiovasculars, però s’ha de continuar la recerca per a millorar els resultats. 
Tradicionalment les estatines s'han utilitzat conjuntament amb inhibidors de l’absorció 
del colesterol, segrestadors d’àcids biliars i fibrats. Recentment s'ha desenvolupat una 
nova família d’hipolipemiants, els anticossos monoclonals inhibidors de la PCSK9, els 
quals mostren resultats prometedors en la prevenció de la malaltia, a l’espera de nous 
estudis de seguretat i eficiència.  
 
 
2. Integration of different fields 
Acute myocardial infarction (AMI) has a great impact on society nowadays. Though 
survival rates have increased along the last years due to new treatment techniques, 
incidence is still high worldwide, causing plenty of both personal and economic costs. 
Therefore, finding improved treatment and mainly primary and secondary prevention 
therapies are key points for AMI management. 
Lipoprotein accumulation in the arterial wall is one of the most important risk factors 
for the atherosclerotic plaque formation and further reduction in the blood flow to the 
heart, causing AMI. This project is focused on primary and secondary pharmacological 
prevention of hyperlipidaemia to reduce AMI risk. Successful prevention of AMI would 
be reflected in greater quality of life for the patients and economic costs reduction for 
the sanitary system. Thus, the main area herein treated is Pharmacology and 
Therapeutics.  
In order to understand how classic therapies operate, why some are more effective than 
others, and to lead research towards new prevention treatments to these events, it is 
necessary to fully understand the processes involved in the pathogenesis of the disease 
at a molecular and biochemical level. This objective will be achieved through the 
secondary areas involved in this project, Physiology and Physiopathology and 




3. Introduction  
Acute myocardial infarction (AMI) is defined as myocardial cell death caused by 
prolonged myocardial ischemia (1). Ischemia is the initial step of AMI development, and 
can be both identified by diffuse chest or upper zone pain, epigastric discomfort, 
dyspnea or fatigue present in the clinical history; or from the electrocardiogram (ECG). 
AMI is classified into atherosclerotic (type 1 AMI) or non-atherosclerotic (including types 
2-5 AMI). 
3.1. Acute Myocardial Infarction types 
3.1.1. Atherosclerotic Acute Myocardial Infarction. Type 1 
Type 1 AMI is a chronic inflammatory disease of the arterial wall defined as spontaneous 
myocardial infarction related to atherosclerotic plaque rupture. It has traditionally been 
divided into ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial 
infarction (NSTEMI). 
STEMI entails abruptly complete blockage of the vessel lumen after the disruption of an 
atherosclerotic plaque and its release to the blood, favouring thrombogenesis and 
artery occlusion. ST-segment elevation appears during the initial stage because of a total 
occlusion of an epicardial  coronary artery, and most patients ultimately evolve Q waves 
on the ECG (Figure 1) (2).  Instead, NSTEMI implies partial blockage of the arterial lumen 
resulting from thrombus forming on a disrupted atherothrombotic coronary plaque or 
eroded coronary artery endothelium. NSTEMI implies ischemic discomfort, without ST-
segment elevation (Figure 1). In both STEMI and NSTEMI appear variations in serum 
cardiac biomarkers of necrosis like cardiac troponins (cTn). (3).  
cTn are contractile regulatory proteins widely used for the diagnosis of acute coronary 
syndrome (ACS), which includes patients presenting stable angina and those with AMI. 
They are only mildly elevated in other 
cardiac conditions other than AMI and 
highly specific for myocardial injury. 
Therefore, quantification of cTn levels is 
required.  





Type 1 AMI is characterized by the detection of a rise or fall of cTn values with at least 1 
value above the 99th percentile upper reference level (URL) and at least one of the 
following: 
- Symptoms of acute myocardial ischemia 
- New ischemic ECG changes 
- Development of pathological Q waves 
- Imaging evidence of new loss of viable myocardium or new pattern consistent 
with an ischemic etiology 
- Identification of a coronary thrombus by angiography including intracoronary 
imaging or by autopsy 
This review will focus on type 1 AMI since it is the most common one. Therefore, it is 
briefly described in this section to be extensively discussed later.  
3.1.2. Non-atherosclerotic Acute Myocardial Infarction. Types 2-5 
Type 2 AMI: Myocardial infarction secondary to an ischemic imbalance  
The ischemic imbalance between the oxygen supply and demand of this AMI can be 
attributed to different systemic causes, none of which may be of atherosclerotic origin. 
Among these causes we can find conditions like hypoxemia, severe bradyarrhythmia, 
severe hypotension, hypertension or anemia, myocardial perfusion reduction, 
spontaneous coronary artery dissection, vasospasms, coronary embolism and 
microvascular dysfunction (1, 4). 
Type 2 AMI is characterized by the detection of a rise or fall of cTn values with at least 1 
value above the 99th percentile URL and evidence of an imbalance between myocardial 
oxygen supply and demand unrelated to acute coronary atherothrombosis and at least 
one of the following: 
 Symptoms of acute myocardial ischemia 
 New ischemic ECG changes 
 Development of pathological Q waves 
 Imaging evidence of new loss of viable myocardium or new pattern consistent 





Type 3 AMI: Myocardial infarction resulting in death when biomarker values are 
unavailable  
Diagnosing this type of AMI may be challenging. Patients suffer cardiac death, with 
symptoms suggestive of myocardial ischemia, ECG changes or ventricular fibrillation, but 
die before blood samples for biomarkers can be obtained or increases in cardiac 
biomarkers can be identified. It can also be detected by autopsy examination (1, 4). 
Type 4a AMI: Myocardial infarction related to percutaneous coronary intervention 
(PCI) 
Coronary intervention-related AMI is arbitrarily defined as an elevation of cTn values >5 
times the 99th percentile URL in patients with normal baseline values. In patients with 
elevated pre-procedure cTn in whom the cTn levels are stable (≤20% variation) or falling, 
the post-procedure cTn must rise by >20% (1, 4). However, the absolute post-procedural 
value must still be at least 5 times the 99th percentile URL. Type 4a AMI is characterized 
by the detection of the above mentioned cTn variations and at least one of the following: 
 New ischemic ECG changes 
 Development of pathological Q waves 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality in a pattern consistent with an ischemic etiology 
 Angiographic findings consistent with a procedural flow-limiting complications 
such as coronary dissection, occlusion of a major epicardial artery or a side 
branch occlusion/thrombus, disruption of collateral flow or distal embolization 
Type 4b AMI: Myocardial infarction related to stent thrombosis  
A subcategory of PCI-related AMI is stent/scaffold thrombosis, as documented by 
angiography or autopsy using the same criteria utilized for type 1 AMI. In this AMI type, 
it is important to consider the time of occurrence of the stent/scaffold thrombosis in 
relation to the timing of the PCI procedure (1, 4). 
Type 5 AMI: Myocardial infarction related to coronary artery bypass grafting (CABG) 
During a CABG procedural, myocardial injury is related to numerous factors, such as any 
potential ischemic injury, the extent of the direct traumatic injury to the myocardium or 
the details of the cardiac preservation, causing a rise in the cTn levels. CABG-related AMI 




patients with normal baseline cTn values. In patients with elevated pre-procedure cTn 
in whom cTn levels are stable (≤20% variation) or falling, the post-procedure cTn must 
rise by >20% (1, 4). However, the absolute post-procedural value still must be >10 times 
the 99th percentile URL. Type 5 AMI is characterized by the detection of the above 
mentioned cTn variations and at least one of the following: 
 Development of pathological Q waves 
 Angiographic documented new graft occlusion or new native coronary artery 
occlusion 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality in a pattern consistent with an ischemic etiology 
3.2. Type 1 spontaneous Acute Myocardial Infarction 
3.2.1. Epidemiology 
Cardiovascular diseases are the 
leading cause of death worldwide 
(1). With an increasing frequency, 
although with large variations 
between countries, they mostly 
result from ischemic heart and 
cerebrovascular diseases (Figure 2). 
(5) 
According to recent data retrieved from Eurostat, the statistical office of the European 
Union, in EU-28 there were 1.83 million deaths reported in 2016 as diseases of the 
circulatory system, corresponding to the 35.7% of all deaths. 118,824 of these deaths 
were in Spain and, among them, 14,908 were due to acute myocardial infarction. 
Between 2013 and 2016, the coronary heart disease (CHD) prevalence in America was 
approximately 6.7% among the Americans ≥20 years, 7.4% corresponding to men and 
6.2% to women (6). Regarding AMI, the prevalence was also bigger among men (4%) 
than women (2.3%) except among those in the range of 20-39 years old. The estimated 
annual incidence of AMI was 605,000 new attacks and 200,000 recurrent attacks. The 
average age at which AMI occurs among women is 72.0 years and among men 65.6 
years.  
Figure 2. Percentage breakdown of deaths attributable to 




3.2.2. Prognosis  
Of all the people who experience a coronary event, 35% of them will die as a result of it 
in the following year, as well as 14% of those experiencing an AMI (6). Furthermore, the 
median survival time after the first AMI in people ≥45 years old is 8.2 years for men and 
5.5 years for women, and within 5 years after the AMI, 17% of men and 21% of women 
will have a recurrent AMI. According to the PROSPECT (Providing Regional Observations 
to Study Predictors of Events in the Coronary Tree) study, the risk of suffering a recurrent 
cardiovascular (CV) event is around 20% in the following three years after an ACS (7).  
If successful early reperfusion or preserved left ventricular function among other factors 
are proceed, it will be associated with a better prognosis, although it is highly variable. 
In contrast, if the patient suffers from previous vascular diseases, diabetes mellitus type 
2 (T2DM) or poorly preserved left ventricular function among other factors, it will be 
associated with a poorer prognosis. Elderly and diabetic patients can present AMI 
without symptoms, making its diagnostic and, therefore, its treatment harder, reflected 
in aggravated prognosis.  
3.2.3. Signs and symptoms 
AMI symptoms can be varied and differ between men and women. In addition, we must 
take into consideration that they can occur with different severities in each patient, 
though they are the same between STEMI and NSTEMI. The first symptom usually is 
deep, visceral pain, often radiating to the back, jaw, left or right arm, shoulders or any 
of the upper body areas that lasts more than a few minutes or that goes away and comes 
back. This discomfort is usually diffuse, and accompanied with nausea and vomiting, 
dyspnea or diaphoresis (8). 
While chest pain is among both men and women the most commonly reported 
symptom, women are more likely than men to have jaw and upper back pain, shortness 







3.2.4. Pathophysiological mechanisms of type 1 Acute Myocardial Infarction 
Type 1 acute myocardial infarction is most commonly due to the disruption of a 
vulnerable atherosclerotic plaque or erosion of the coronary artery endothelium, 
leading to the decrease of the myocardial blood flow with ensuing myocyte necrosis (9).  
Atherosclerotic plaques are usually formed in the lumen of medium sized and large 
arteries curvatures, branch points and bifurcations. Dyslipidaemia, together with T2DM, 
is one of the most firmly established risk factors for atherosclerosis and, therefore, type 
1 AMI. Elevated LDL levels are the main risk factor for atherosclerotic plaque formation. 
However, diabetic dyslipidaemia is mostly characterized by increased levels of large 
very-low-density lipoprotein (VLDL) particles, which generate atherogenic remnants, 
small and dense LDL particles and triglyceride (TG), as well as dense high-density 
lipoprotein (HDL) particles. Tobacco consumption, hypertension, turbulent flow and 
inflammatory diseases are also other risk factors for type 1 AMI because of their ability 
to trigger lesions in the intima, damaging the blood vessels wall and, therefore, 
favouring atherosclerosis (3).  
These lesions in the intima, the innermost layer of the vessels wall, will cause its 
dysfunctionality. Tunica intima consists of an endothelial cells monolayer that provides 
the interface between circulating blood and the rest of the vessel wall. In a normal state 
produces nitric oxide (NO), a signalling molecule with important functions on the vessel 
wall as relaxation and inhibition of proliferation of vascular smooth muscle cells (VSMC), 
inhibition of activation and aggregation of platelets and inhibition of inflammation 
caused by cell adhesion and migration (10).  
Endothelial dysfunction  causes a reduction in NO production while stimulates adhesion 
molecules production, attracting inflammatory cells to the intima, and resulting in an 
environment conductive to the development of atherosclerosis (10). It also causes an 
increase in lipoproteins permeability and favours their retention in the intima by 
extracellular matrix molecules (11). Then, LDL particles can undergo oxidative 
modifications becoming oxLDL, which stimulate monocytes and adhesion molecules 




Monocytes will differentiate into macrophages via macrophage colony-stimulating 














If the circulating level of lipoproteins is bigger than the phagocytic capacity of the 
monocytes, macrophages will act chemotactically upon more monocytes and smooth 
muscle cells, which in turn will phagocyte more lipids and become foam cells.  
Macrophages synthesize pro-inflammatory cytokines, which recruit VSMC from the 
media layer to the intima (13). Extracellular matrix increase in dense by VSMC replication 
and production of collagen and elastin, contributing to the development of the fibrous 
cap. A strong fibrous cap that will isolate the lipid core from circulating blood is formed, 
stabilizing the plaque but also narrowing the vessel lumen. 
End result lesion is a subendothelial fibrous plaque composed of lipid core surrounded 
by VSMC and connective tissue fibres. Unstable plaques have thick lipid core but thin 
Figure 3. Infiltration of low-density lipoprotein (LDL) and formation of macrophage foam cells in the arterial wall. 
LDL particles are prone to infiltration and retention in the arterial wall, where they will undergo oxidative 
modifications becoming oxLDL, which promote monocyte recruitment to the arterial wall. These monocytes will 
differentiate into macrophages, engulf the oxLDL and become foam cells, which will stimulate inflammation by the 
release of pro-inflammatory cytokines (12). 
LDL: low-density lipoprotein; oxLDL: oxidized low-density lipoproteins; M-CSF: macrophage colony-stimulating factor; 
VCAM-1: Vascular Cell Adhesion Molecule 1; ICAM-1: Intercellular Adhesion Molecule 1; CD36: cluster of 





fibrous cap, making them more susceptible to rupture than stable plaques, with low lipid 
contend but thick fibrous cap (14).  
Many of the involved macrophages undergo apoptosis and are removed by other 
macrophages. If this process happens successively, macrophage death occurs with its 
consequent release of lipids, pro-inflammatory mediators and metalloproteinases 
(MMPs) in the intimal lesion (13), increasing collagen degradation and rending the cap 
susceptible to rupture (3).  T-lymphocytes enter the intima and regulate functions of the 
innate immune cells. Activated T-helper cells secrete cytokine interferon gamma (IFN-γ) 
which inhibits the production of the new interstitial collagen that is required to repair 
and maintain the fibrous cap that protects the plaque. 
Gradual loss of VSMCs and collagen-rich cap matrix degradation lead to fibrous cap 
thinning and rupture with subsequent release of its thrombogenic material into the 
blood flow. These events will result in platelet adhesion and thrombus formation, 
triggering inflammation. 
AMI arises from an atherosclerotic plaque rupture and following clot formation, but 
rather than with vessel stenosis itself, it is related with plaque enlargement. Likelihood 
of plaque rupture is increased with thick necrotic core, thin fibrous cap, positive 
remodelling and large plaque burden. Thus, an increase in necrotic core volume and 
fibrous cap attenuation turns out to be a major risk factor for plaque rupture. Contrarily, 
necrotic core volume diminution and calcification, even if it implies heightened luminal 
stenosis, leads to plaque regression. Therefore, plaque stabilization becomes a key 
target in atherosclerosis prevention and regression and, consequently, for AMI 
prevention. 
According to the American Heart Association (AHA), atherosclerosis can be divided into 












Patients with ischemic heart disease are divided into two groups: those with chronic 
coronary artery disease (CAD) presenting stable angina and those with ACS. The latter 
includes patients with STEMI and NSTEMI, with evidence of myocyte necrosis, and 
patients with unstable angina without myocyte necrosis evidence (3). It is important to 
differentiate between unstable angina and AMI, as their treatment will be different. A 
patient experiencing AMI will not relief his/her symptoms while resting as it is owing to 
ischemic necrosis due to prolonged lack of blood flow and oxygen during a prolonged 
period. Instead, a patient suffering from angina will feel chest pain during exercise or 
emotional stress, with relief of symptoms while resting. 
A patient with suspected AMI should have an initial evaluation that includes physical 
examination, focused clinical history, cardiac biomarkers quantification and 
electrocardiogram. This will help the physician to assess the severity of AMI and to 
distinguish between different ACS events, such as STEMI and NSTEMI, as well as unstable 
angina. For instance, AMI presents with a rise or fall in cTn levels, whereas the last one 
displays normal cardiac biomarker values.   
Figure 4. Evolution and progression of atherosclerosis lesion. Type I lesion: First microscopically detectable lipid 
deposits in the intima. Monocyte recruitment from the vessel lumen into the intima and evolution to macrophages. 
These macrophages engulf lipoproteins becoming foam cells and begin to produce pro-inflammatory and adhesion 
molecules. Type II lesion: Macrophage foam cells stratify in adjacent layers forming a fatty streak. Type III lesion: 
Intermediate lesion with extracellular lipid accumulation defined as preatheroma. Type IV lesion: First advanced 
lesion defined as atheroma. With high lipid contend (lipid core formation), intimal disorganization and arterial 
deformity. Type V lesion: Reparative connective tissue (mainly composed by collagen and elastin) and fibrous plaque 
formation around the lipid core defined as fibroatheroma. Type VI lesion: Fibrous plaque rupture with consequent 




3.2.6. Acute treatment 
In this section, acute treatment after Type 1 AMI is discussed, both for STEMI and 
NSTEMI. Even though both are classified as Type 1 AMI and have an atherosclerotic 
origin, there are some differences in their pathophysiology as it has been previously 
described in this review. Therefore, their treatment must be differentiated. Primary and 
secondary prevention, focused on lipid-lowering therapies, will be further discussed in 
section 6. 
3.2.6.1. ST Elevation Acute Myocardial Infarction 
Myocardial necrosis in AMI begins 15-30 minutes after severe ischemia. At present, the 
main treatment strategy is revascularization by percutaneous coronary intervention 
(PCI) within the first 120 minutes since the symptoms presentation (18). It is essential 
that initial assessment and management be rapid to be able to start the treatment as 
soon as possible to increase the myocardial salvage tissue and reduce mortality. 
Thereby, a patient diagnosed with STEMI should be referred to a PCI-capable hospital to 
reach a performance goal of ≤90 minutes from the first medical contact.   
PCI performance is preferred over fibrinolytic therapy because of its lower rates of 
haemorrhage, early death and reinfarction. When patients arrive to the PCI-capable 
hospital 12-24 hours after the symptom onset, PCI is only recommended if ischemic 
symptoms persist. After 24 hours, if symptoms persist and PCI is not available, the 
elected therapy is fibrinolytic (18). 
Initial interventions 
Once STEMI diagnostic is made, continuous ECG monitoring should be proceed.  
Supplementary oxygen should be administered to patients with an arterial saturation 
below 90% (19). However, it has been proved that routine administration of oxygen once 
achieved 90% saturation does not decrease the individual risks of recurrent cardiac 
events and makes no difference in the rate of the primary endpoint of death or 
rehospitalization with AMI within one year (20).  
Pharmacotherapy should be started after the first medical contact to relive ischemic 
pain, and nitrates administration is widely used; 0.4 mg of sublingual nitroglycerin is 
administered to improve symptoms and lower blood pressure (21).  In patients with an 




morphine therapy is not recommended because it is associated with higher adjusted risk 
of death than those not treated, and neither nonsteroidal anti-inflammatory drugs 
(NSAID) are recommended, since prothrombotic events are associated with their use 
(22). 
Antiplatelet treatment 
According to the AMI code in Catalonia, antiplatelet treatment should be started as soon 
as possible, consisting in Aspirin administration together with a P2Y12 antagonist, as it 
has established benefit in primary and secondary prevention of AMI, whether later PCI 
or fibrinolytic strategy will be proceed (21). 
The combined treatment with Aspirin and a P2Y12 inhibitor is defined as dual 
antiplatelet treatment (DAPT) (23). Aspirin is a thromboxane A2-dependent platelet 
aggregation inhibitor, and it is administered with a per os (p.o.) dose of 250 mg (21). 
P2Y12 is a Gi-coupled receptor which reduces cAMP intracellular levels, essential to 
platelet activation. Platelet activation can be inhibited with a P2Y12 antagonist, rather 
irreversibly with clopidogrel or prasugrel, or reversibly with ticagrelor (23). 
To achieve maximum efficacy, prompt initiation of P2Y12 inhibitor should be proceed. 
Clopidogrel, ticagrelor or prasugrel will be administered previously to the PCI according 
to the criteria described in Figure 5. If the patient will later undergo fibrinolytic 
treatment instead of PCI, he/she should  receive 300 mg p.o of clopidogrel for patients 
<75 years old or 75 mg p.o for patients >75 years old. Prasugrel and ticagrelor have a 
more rapid onset of action and greater potency than clopidogrel. Therefore, its use is 






Anticoagulant treatment is recommended for all patients experiencing an AMI in 
addition to antiplatelet treatment, before PCI or fibrinolytic procedure. Anticoagulant 
alternatives include unfractionated heparin (UFH), low-molecular-weight heparin or 
enoxaparin, and the synthetic drug bivalirudin.  
While the ATOLL (Acute myocardial infarction Treated with primary angioplasty and 
intravenous enOxaparin or unfractionated heparin to Lower ischaemic and bleeding 
events at short- and Long-term follow-up) trial showed significant reductions in 
Figure 5. Antiplatelet therapeutic options. If the patient or a family member cannot be interrogated to know about 
the patient history or he/she suffers from known high risk haemorrhage, 600 mg p.o of clopidogrel will be 
administered. Patients without high risk for haemorrhage but under DAPT will receive a loading dose of 180 mg p.o 
of ticagrelor. Diabetic patients or with extensive AMI will receive 60 mg p.o of prasugrel. Finally, if he/she does not 
meet any of the above conditions, 600 mg p.o of clopidogrel will be administered. Adapted from AMI code in 






mortality and major bleeding over UFH, the MATRIX (Minimizing Adverse haemorrhagic 
eEvents by TRansradial access site and systemic Implementation of angioX) trial showed 
no improvements of bivalirudin over UFH (24). Therefore, enoxaparin is preferred over 
the other options, with greater safety and efficacy, administrating 70 international unit 
(i.u)/kg dose with a maximum of 5,000 i.u (21). 
Fibrinolytic treatment  
Fibrinolytic therapy enhances blood clot elimination after an AMI, but it will only be 
administered if PCI performance is not available, since its combination is related with 
higher haemorrhage risk. Tenecteplase is a fibrin-specific tissue plasminogen activator. 
It promotes the degradation of plasminogen into plasmin, which in turn degrades the 
fibrin matrix of the thrombus. Tenecteplase is the drug of choice since it is has 
comparable efficacy to the other fibrinolytics commercialized but it is related with less 
non-cerebral bleeding. It is administered as a single bolus up to 50 mg, according to the 
patient's weight (25).  
3.2.6.2 Non ST Elevation Myocardial Infarction 
The protocol treatment for NSTEMI after the first medical contact is similar to the one 
set for STEMI treatment. Supplementary oxygen and nitroglycerin should follow the 
same administration recommendations, and NSAIDs are also misadvised. In the same 
way, DAPT with 250 mg of Aspirin and the chosen P2Y12 inhibitor is administered (26). 
In NSTEMI patients managed with an invasive strategy, UFH is the recommended 
anticoagulant, but for patients managed with a conservative strategy, the synthetic 
anticoagulant fondaparinux or the low-molecular-weight heparin enoxaparin are 
preferred (27).  
Prospective trials have demonstrated that fibrinolytic therapy may increase 
haemorrhagic risk in patients with NSTEMI (28) and, therefore, its use is misadvised. In 
unstable patients urgent PCI is performed, but given the residual perfusion in the 
ischemic zone, revascularization can be delayed for patients at lower immediate risk. 
However, timing can vary depending on the presence or absence of high risk features. If 
initial treatment with DAPT and ischemic pain relieve therapy stabilized the patient, PCI 





Cardiovascular diseases, including acute myocardial infarction, still remain the leading 
cause of death worldwide, with a great incidence and impact on society. Benjamin et al. 
state that 35% of those experiencing a coronary event will die as a result of it in the 
following year. According to Schiele et al., the risk of suffering a recurrent cardiovascular 
event is around 20% in the following three years after an acute coronary syndrome. 
Therefore, therapeutic alternatives need to be found to diminish this recurrence, as well 
as to reduce primary events. 
The main objective of this review is to summarize the current mainly used lipid-lowering 
therapies for primary and secondary prevention of AMI, in order to be able to 
understand the actual management of the disease.  
The main currently used lipid-lowering therapies are statins, cholesterol absorption 
inhibitors, PCSK9 inhibitors, bile acid sequestrants and fibrates. Statins are established 
as the leading therapy for primary and secondary prevention of AMI, but are sometimes 
related with severe adverse effects like myalgias. In this case, a dose reduction or even 
the treatment interruption is needed. Alternately, combined therapy of another lipid-
lowering drug on top of the current statin treatment, although with lower doses, shows 
improved outcomes. This review aims to perform an exhaustive bibliographic research 
to understand its physiopathology and to assess the current management, to be able to 
direct research in the future towards new perspectives. 
To be able to do so, secondary goals complementary to the main one are established to 
reach a global vision of the disease: 
- Distinguish the different features that characterize acute myocardial infarction 
types, focusing on type 1. 
- Contextualise through epidemiological studies the relevance of the disease 
worldwide. 
- Comprehend the pathophysiology involved in the atherosclerosis process. 






5. Material and methods 
In order to perform an updated bibliographic inquiry, an exhaustive research has been 
carried out mainly in PubMed and Uptodate databases, focusing in reviews from the 
past 5 years. Keywords for strategic research were: “acute myocardial infarction”, 
“prevention”, “treatment”, “atherosclerosis pathophysiology”, “dyslipidaemia”, “lipid-
lowering”, “statins” and “adverse effects”. However, some older reviews regarding 
mainly the pathophysiology of the disease have been used. In this case, also the 
textbook Harrisons – Principles of internal medicine (3) was useful. The core of this 
review is based on information obtained from guidelines of la Generalitat de Catalunya 
(Canal Salut) to be fully adapted to our geographic scope; and from The European 
Society of Cardiology, Eurostat, the American College of Cardiology and the American 
Heart Association to have a global viewpoint. Moreover, all the literature used to write 
this project is referenced with Mendeley®. 
6. Results and discussion 
Plasma lipoproteins, responsible of cholesterol and triglycerides transport in blood, can 
be divided, according to their size and density, into six different classes: chylomicrons, 
very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density 
lipoprotein (LDL), high-density lipoprotein (HDL) and lipoprotein (a) (Lp(a)) (29).  
LDLs are the lipoproteins with higher capacity of cholesterol transport and, therefore, 
the most representative indicator of atherosclerotic plaque formation risk. VLDL 
particles, synthetized in the liver, carry most of the circulating TG, also associated with 
increased atherogenic risk. A patient suffering from hypertriglyceridemia will have 
abnormal VLDL particles, which will difficult their catabolism through hepatic LDL 
receptor (LDLR) and cannot be properly hydrolysed by lipoprotein lipase (LPL). The result 
are small and dense LDL particles, highly atherogenic, more susceptible to oxidation and 
recognition by macrophages, which will engulf this oxLDL and become foam cells. 
Instead, HDL is the only lipoprotein with anti-atherogenic properties, transporting 
cholesterol to the liver. 
Over time, large clinical trials have shown that lipid-lowering treatment has a great 
impact on AMI risk reduction in patients with dyslipidaemia (30) by both reducing 




can be classified into hypercholesterolemia (elevated LDL levels), hypertriglyceridemia 
(elevated TG levels) and mixed hyperlipidaemia (elevated LDL and TG levels, usually 
accompanied by decreased HDL levels) (31). Accordingly, the lipid-lowering treatment 
will vary depending on the therapeutic goal, whether it be to reduce LDL, TG or both. 
Data have proved a direct relation between the concentration of circulating LDL and the 
atherosclerotic plaque initiation with its consequent thrombus formation and blood 
flow obstruction, leading to AMI. Meta-analyses have confirmed a dose-dependent 
reduction in CV risk with the absolute LDL reduction (32). Furthermore, increases in HDL 
are associated with atherosclerosis reduction, at the same time that decreases in HDL 
are related with increased AMI risk, even though having low LDL levels (29).  
At a population level, the risk factors modification has shown an important decrease in 
the hospitalization rates for AMI. Aiming to improve treatment benefits, the European 
Society of Cardiology (ESC) establishes specific objectives for each patient. LDL reduction 
goals are established according to the initial risk stratification (Table 1). 
Table 1. Recommendations for treatment goals for low-density lipoprotein cholesterol. Adapted from Mach et al. 




For primary and secondary prevention of atherosclerotic CV diseases, The American 
College of Cardiology and American Heart Association (ACC/AHA) stratifies patients 
according to their risk of suffering a CV event. This classification is based on baseline LDL 
levels, history of previous events and the presence or absence of comorbidities like 
diabetes mellitus or metabolic syndrome. Pursuant to this classification, treatment 
options and intensity will be recommended. 
Below are shown the most efficient and, therefore, prescribed lipid-lowering therapies 
used nowadays for primary and secondary prevention of AMI. For that reason, these five 
therapeutic families are discussed in this review (Figure 6):  
1. 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors or 
statins 
2. Niemann-Pick C1-like protein 1 (NPC1L1) or cholesterol absorption inhibitors  
3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
4. Bile acid sequestrants 
5. Peroxisome proliferator-activated receptor α (PPAR-α) agonists or fibrates 
 
 





6.1. 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors or 
statins 
Statins are reversible competitive 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) 
reductase inhibitors. In addition to competing with cholesterol for binding to the 
enzyme, they alter its conformation, thus preventing HMG-CoA reductase from attaining 
a functional structure. HMG-CoA reductase is the rate-limiting enzyme responsible for 
the conversion of HMG-CoA into mevalonic acid, a cholesterol precursor. Thus, statins 
reduce endogenous cholesterol synthesis (33). When cholesterol production in 
hepatocytes decreases, hepatic expression of LDLR increases, leading to the reduction 
of circulating LDL and its precursors (34).  
Patients suffering from previous AMI, T2DM or chronic kidney disease are considered 
individuals with very high risk for another CV event. To be able to achieve the objective 
of ≥50% reduction from baseline LDL levels, high intensity statin therapy is 
recommended. Two drugs are considered in this situation: atorvastatin with a daily oral 
dose of 40-80 mg and rosuvastatin with a daily oral dose of 20-40 mg (35).  
Statins do not only reduce CV risk by reducing endogenous cholesterol synthesis, but 
they also display pleiotropic effects (Table 2). 
Additional effects of statins 
HDL increases Statins show cardioprotective effects by increasing HDL levels, usually by a 
5% to 10%. Although it is very modest compared with the LDL levels 
reduction, it is of great importance 
Effects on endothelial 
cell functions 
Hypercholesterolemia treatment also enhances endothelial functionality. 
This is essential to be able to produce NO, which inhibits VSMSC 
proliferation, the activation and aggregation of platelets and the 
inflammation caused by cell adhesion and migration (10) 
Effects on the 
inflammatory process 
GTPases are key proteins for the cytokines receptors functionality. Statins 
can prevent their isoprenylation and, therefore, inhibit cytokine function, 
reducing the inflammatory response 
Effects on proliferation 
and migration of  
smooth muscle cells 





Effects on the stability 
of the atherosclerotic 
plaque 
Statins reduce both MMP production and activity, responsible of the fibrous 
cap degradation. Thus, they enhance plaque stability, a key factor in plaque 
rupture and consequent AMI prevention  
Effects on platelet 
activation 
Increased levels of LDL are related with increased platelet reactivity after the 
fibrous cap rupture. Statin therapy showed a reduction of platelet 
aggregation induced by ADP 
Effects on the 
coagulation process 
Statins have also proven to reduce thrombus formation through mevalonate 
pathway inhibition 
 
Table 2. Additional effects of statins (33). 
 
Although atorvastatin and rosuvastatin are the most potent statins available for LDL 
levels reduction, there are other statins recommended for patients with a lower CV risk. 





Clinical trials outcomes have positioned statins as the leading treatment for primary and 
secondary prevention of AMI (37). A meta-analysis of randomised trials published in 
June 2009 shows the benefits of statins in patients with cardiovascular risk factors but 
without established cardiovascular diseases (38). Even though different statins at 
different doses were evaluated during a mean follow-up of 4.1 years, statin treatment 
was clearly associated with a 30% risk reduction in CV events. Furthermore, the CTT 
(Cholesterol Treatment Trialists’) meta-analysis showed a 23% reduction in mortality of 
CV disease and non-fatal MI over five years after statin treatment, achieving a 38.7 
mg/dL reduction in LDL levels (39). 
Dose (mg of agent) % Reduction 
Atorvastatin Rosuvastatin Pitavastatin Simvastatin Lovastatin Pravastatin Fluvastatin TC LDL-C 
   20  20 20 40 22 27 
10 5 1 40 40 40 80 27 34 
20 10 2 80 80 80  32 41 
40 20 4     37 48 
80 40      42 55 




Maximum risk reduction of CV events by 30% at the higher tolerated statin doses, 
suggest that CV risk is not only conditioned by high plasma LDL concentrations, but 
shows the implication of other lipoproteins. Furthermore, statins effect is limited in 
obese and T2DM patients, characterized by small and dense LDL, high TG levels and low 
HDL levels, largely related with increased CV risk. These findings suggest that the 
hyperlipidaemia treatment and subsequent AMI prevention relies not only in LDL 
lowering therapies but also in cardioprotective approaches (40). This topic will be 
further discussed in section “6.5. Residual risk”. 
Adverse effects 
Statins are safe and well tolerated drugs. However, their use have been related with 
myotoxicity, mainly with high statin doses (41). While myopathy is the most clinically 
adverse effect reported, rhabdomyolysis is the most severe (29). Myopathy is defined 
as muscle symptoms and creatine kinase levels elevation. According to the PRIMO 
(Prediction of Muscular Risk in Observational Conditions) study (42), myopathy occurs 
with myalgia, muscle tenderness, heaviness, stiffness, cramps or weakness and is usually 
intensified with exercise. Rhabdomyolysis is characterized by severe muscular pain, 
muscle necrosis and myoglobinuria, potentially leading to renal failure and death (29). 
It is most commonly due to interactions with other drugs. Its incidence may vary 
according to the different statins usage, since they are metabolized by different 
cytochrome P450 isoforms, which can be inhibited by different drugs. Thus, many 
patients cannot tolerate a dose sufficient to reach their LDL goal, showing the benefits 
of a combined therapy (43). Currently, the only way to avoid this toxicity is the reduction 
of doses or the interruption of the administration. 
6.2 Niemann-Pick C1-like protein 1 (NPC1L1) or cholesterol absorption inhibitors 
Plasmatic LDL levels can also be reduced by inhibiting intestinal cholesterol absorption. 
Ezetimibe is a drug capable of inhibiting Niemann-Pick C1-like protein 1 (NPC1L1), the 
major cholesterol transport protein in enterocytes. NPC1L1 inhibition causes a reduction 
in intestinal cholesterol absorption but without affecting the absorption of fat-soluble 
nutrients. Thus, delivered cholesterol amounts to the liver are reduced, causing an 
upregulation of LDLR expression and increasing LDL clearance from the blood (29). 
However, inhibition of cholesterol absorption is usually followed by an increase in 




reduced about a 15 to 20% with the NPC1L1 inhibition by ezetimibe (29). Given that 
ezetimibe is not usually prescribed as monotherapy and there are no studies on the 
cardiovascular benefits of using ezetimibe alone, this review focuses only on its 
beneficial effects in combination with other lipid-lowering drugs. 
When maximum or maximum tolerated statin doses are not enough to achieve LDL 
reduction goals, addition of a complementary agent can be beneficious for the patient. 
Ezetimibe has a mechanism of action supportive to that of statins. Therefore, it is well 
combined with statins in hypercholesterolemia treatment. It has been proved that 10 
mg of ezetimibe added to the ongoing statin treatment has 22-26% LDL levels reduction 
beyond statins monotherapy (44). As secondary prevention, the IMPROVE-IT (Improved 
Reduction of Outcomes: Vytorin Efficacy International Trial) trial has demonstrated that, 
after a median follow-up of seven years, patients with ACS treated with the association 
of ezetimibe and simvastatin had lower rates of CV events than those with simvastatin 
alone (45). An absolute risk reduction of 2% was observed in the combined therapy 
group above the simvastatin monotherapy group. Contrarily, there were no observed 
reductions in cardiovascular death rates in neither group. This trial showed, in the 
diabetic subgroup, a 5.5% absolute risk reduction and a 14% relative risk reduction in CV 
events after a combined therapy of 40 mg p.o of simvastatin with 10 mg p.o of ezetimibe 
over 40 mg p.o of simvastatin monotherapy. Thus, the IMPROVE-IT trial showed greater 
reductions in CV events risk in diabetic patients than in non-diabetic (46). 
The PRECISE-IVUS (Plaque Regression with Cholesterol absorption Inhibitor or Synthesis 
inhibitor Evaluated by IntraVascular UltraSound) study showed a 2.3% plaque regression 
after ezetimibe on top of statin treatment in patients with ACS. With statin 
monotherapy, only a 0.2% plaque regression was observed (39).  
People with chronic kidney disease are considered high risk patients for CV events, and 
they are most likely to be intolerant to high statin doses. The SHARP (Study of Heart and 
Renal Protection; available at clinicaltrials.gov and registered as NCT 00125593) study 
analyses the benefits of simvastatin plus ezetimibe combined therapy in patients with 
chronic kidney disease. Results showed a one-sixth fewer major atherosclerotic events 
in patients under 20 mg p.o of simvastatin and 10 mg p.o of ezetimibe compared with 




number of studies show the effectiveness of lipid-lowering treatments in CV risk 
reduction, but this trial was the first one to demonstrate its benefits in patients with 
kidney disease.  
Thereby, besides decreasing CV events rates and improving outcomes, the combined 
therapy of ezetimibe on top of low-dose statin treatment can be helpful to patients 
intolerant to high statin doses.  
Adverse effects 
Ezetimibe has been shown to be safe, tolerable and effective at lowering LDL levels, 
either alone or in combination with statins (43). Combination therapy of ezetimibe plus 
statins has shown to achieve the LDL reduction goals with an overall safety similar to the 
respective monotherapies. During the SHARP study, no severe adverse effect was 
reported, in the muscles, as high statin doses showed, in the liver or any of the other 
organs. 
6.3. Proprotein convertase subtilisin/kexin type 9 inhibitors 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are the most novel lipid-
lowering drugs available. PCSK9 are circulating proteins responsible of LDLR catabolism. 
PCSK9 proteins have become a therapeutic target, since their inhibition leads to an 
increase in LDLR expression and, therefore, a rise in LDL uptake and plasma 
concentrations reduction (29). Monoclonal antibodies (mAb) have been developed 
targeting these proteins. Currently, the only drugs approved are alirocumab, 
commercialized as Praluent, and evolocumab, commercialized as Repatha. In clinical 
trials, they have shown average LDL reduction by 60%, achieving LDL reduction goals. A 
small TG reduction and HDL increase has also been related with these mAb (29).  
The GLAGOV (Global Assessment of Plaque Regression with a PCSK9 Antibody as 
Measured by Intravascular Ultrasound) trial assessed the effects on plaque reduction by 
evolocumab after statin treatment.  LDL levels were diminished to 36.6 mg/dL after the 
mAb treatment and the coronary plaque volume was reduced by a 64.3%, compared 
with LDL levels of 93.0 mg/dL and a 47.3% reduction in coronary plaque volume after 




The FOURIER (Further Cardiovascular Outcome Research with PCSK9 Inhibition in 
Subjects with Elevated Risk) trial assessed the effects of the injection of 140 mg of 
evolocumab every 2 weeks after statin treatment for secondary prevention of CV 
diseases. For primary endpoint risk, namely cardiovascular death, myocardial infarction, 
stroke, hospitalization for unstable angina, or coronary revascularization, after one year 
of treatment with evolocumab, a 12% risk reduction was observed, which was further 
reduced up to 19% over time (47). In terms of individual outcomes, MI risk was reduced 
by a 27%, but there were no observed reductions in cardiovascular death rates. 
Furthermore, the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After 
an Acute Coronary Syndrome During Treatment With Alirocumab) study showed, after 
a follow-up of 12 months, a reduction in mean LDL levels from 92 mg/dL to 48 mg/dL 
(29). Primary outcomes, namely CHD death, nonfatal MI, ischemic stroke, or unstable 
angina requiring hospitalization, experienced a 15% relative reduction after a median 
follow-up of 2.8 years. However, this study did not show effects on CV death rates either. 
Interestingly, the best effect of PCSK9 inhibitors was observed in a combined therapy 
with statins. PCSK9 inhibitors on top of the maximum tolerated statin dose can reach up 
to a 40 to 70% LDL levels reduction (39). Furthermore, the CREDO Kyoto (Coronary 
Revascularization Demonstrating Outcome study in Kyoto) trial assessed the efficacy of 
140 mg of evolocumab administered every 2 weeks on top of a high-intensity statin 
treatment compared with the statin monotherapy (48). The combined therapy showed, 
after one year of treatment, a 20% reduction in mortality rates, in contradistinction to 
the evolocumab monotherapy, which showed declines in MI risk but had no effect on 
cardiovascular death rates. 
Thereby, although achieving LDL reduction goals, PCSK9 inhibitors do not diminish 
primary endpoint risk as monotherapy. Contrarily, combined therapy with statins 
showed improvements in all primary endpoints, including cardiovascular death risk. 
Adverse effects 
As PCSK9 inhibitors are subcutaneously administered, the interaction risk with orally 
absorbed drugs is reduced. According to the IMPROVE-IT study, until now they have not 
been related with any clear adverse effects, but since they are only commercialized since 




6.4. Bile acid sequestrants 
Cholesterol in the liver can be either packaged into lipoproteins, mainly VLDL, and 
returned to the bloodstream or excreted to the enterohepatic circulation as the main 
component of bile acid. Part of this cholesterol can be later reabsorbed to the liver. Bile 
acid sequestrants bind to bile salts, forming an insoluble complex that will be removed 
from the enterohepatic circulation, preventing the reabsorption of both cholesterol and 
the resin, reducing the bile flow. Thus, new bile acid will be synthetized in the liver from 
new cholesterol particles, decreasing hepatic LDL levels and causing LDLR upregulation 
(29). 
With a maximum daily dose for the exchange resins cholestyramine and colestipol of 24 
g and 20 g respectively or 4.5 g of the synthetic drug colesevelam, it has been proved an 
18 to 25% reduction in LDL levels, being a good alternative to statin intolerant patients 
with hypercholesterolemia but not with hypertriglyceridemia (49). They can also be 
administered in combination with either statins or ezetimibe to achieve the LDL 
reduction goals when they are not reached with statin monotherapy.  Additional 10-16% 
reduction in LDL levels were observed when compared with statin monotherapy. 
Ezetimibe on top of the current bile acid sequestrant treatment showed an additional 
10-20% reduction in LDL levels when compared with bile acid sequestrant monotherapy. 
The CV risk reduction has been proved through clinical trials to be proportional to the 
LDL levels reduction.  
Furthermore, the LRC-CPPT (Lipid Research Clinics Coronary Primary Prevention Trial) 
study assessed the effects of cholestyramine after an average of 7.4 years versus 
placebo. The cholestyramine group experienced on average a 19% reduction in primary 
endpoint, namely CHD and nonfatal MI. LDL reduction was 12.6% greater than that of 
the placebo group. Contrarily, all causes of death rates were not significantly reduced 
(50). 
According to the below presented studies, bile acid sequestrants prove to be effective 






The most common adverse effects reported are gastrointestinal disturbances, including 
constipation, flatulence, stomach pain, vomiting, heartburn, loss of appetite and 
indigestion, and they can be diminished by a gradual dosage increase procedure. They 
can cause a slight TG increase and, therefore, are not indicated for patients with 
hypertriglyceridemia.  
6.5. Residual risk 
As stated above, the CV risk despite LDL-lowering treatment is still high. This is 
commonly referred as residual risk, and includes high TG rich lipoprotein and Lp(a) 
levels, low HDL levels and inflammation (51). It has been previously reported that 
elevated TG levels, low HDL levels and small and dense LDL particles, present in high-
risk patients, can lead to atherosclerosis and, eventually, to AMI. Therefore, additional 
lipid modifying intervention may be needed (52), which will be briefly discussed in the 
following sections. 
6.5.1. Peroxisome proliferator-activated receptor α (PPAR-α) agonists or fibrates 
Fibrates are peroxisome proliferator-activated receptor α (PPAR-α) selective agonists 
prescribed to reduce plasma TG  (53).  PPAR-α are predominantly expressed in the liver, 
where they regulate gene transcription of enzymes involved in lipid metabolism. One of 
the genes modified by PPAR-α is that codifying for the LPL. Therefore, LPL activity is 
increased upon fibrate treatment, which reflects in a TG plasma levels diminution (54). 
Moreover, fibrates increase apolipoproteins A (ApoAs) expression, necessary for HDL 
assembling and functioning. Nowadays, three fibrates are available in the European 
Union: the selective PPAR-α agonists gemfibrozil and fenofibrate, and the pan-agonist 
alpha, beta and gamma bezafibrate. Clinical trials have proven the effectiveness of 
fibrates decreasing plasma TG by a 30% and increasing plasma HDL levels about 9% in 
patients with mixed dyslipidaemia and high TG baseline levels. Nonfatal MI odds were 
reduced by 22% (40). Some fibrates have also proven to decrease LDL but they are much 
less powerful than statins. Therefore, fibrates can be used as monotherapy for 
hypertriglyceridemia treatment and in combination with statins for mixed dyslipidaemia 
(55). Fenofibric acid on top of the current statin treatment shows greater reductions in 
TG, increases in HDL and LDL particles size shift from small to intermediate and large 




Sharma et al. (56) assessed the TG levels reduction after fenofibric acid or statin 
treatment and after their combination with different statin doses. After 12 weeks 
follow-up, fenofibric acid combined with low-dose statin resulted in 52.7% TG levels 
reduction, whereas low-dose statin monotherapy resulted in only 28.5% TG levels 
decrease. Treatment with moderate-dose statin showed a similar trend. The combined 
therapy showed a 53.8% TG levels reduction, and the statin monotherapy a 34.1%. Also, 
the TG levels reduction in this study after fenofibric acid was 39.6%. 
As it has been previously mentioned in this review, T2DM is an important risk factor for 
AMI and ACS in general. Patients with T2DM also display a defective catabolism of TG, 
which reflects in elevated TG levels in plasma and, therefore, increased CV disease risk 
about two-fold on average and increased mortality risk after an ACS (29), worsening 
their prognosis. As an alternative to statin monotherapy, research has been made to 
analyse the benefits of fibrates in AMI risk reduction. The FIELD (Fenofibrate 
Intervention and Event Lowering in Diabetes) trial showed, after 5 weeks under 200 mg 
fenofibrate p.o., a 10% decrease in LDL levels, a 26% decrease in TG levels and a 6.5% 
increase in HDL levels (57).  
Adverse effects 
Fibrates are generally safe and well tolerated. They can cause increases in creatinine and 
homocysteine serum levels, though these have not been associated with an increased 
risk for renal failure in clinical trials (29). The main side effects reported are 
gastrointestinal disturbances and skin rashes. Myopathy is rarely associated with 
fibrates, but when it occurs, treatment must be discontinued. Otherwise, it can lead to 
rhabdomyolysis with its consequent kidney failure and death (58). Fenofibric acid is the 
only fibrate currently used in association with statins due to its lower intervention in 
their metabolism. It does not increase plasma statin concentrations, which could cause 
myopathy. 
6.5.2. Other lipid-lowering drugs 
Fasting TG levels proved effectiveness in long and short-term prediction of CV events in 
patients with ACS under statin treatment, suggesting a relation between fasting TG and 
residual CV risk. In addition, non-fasting TG levels are associated with ischemic disease 




(PUFA) derivative which decreases the availability of non-esterified fatty acids in the 
circulation and, therefore, in the liver. Thus, VLDL synthetized in the liver will have less 
TG content. The REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-
Intervention) trial showed, after one year under 4 g daily of icosapent ethyl on top of 
statin treatment, an 18% reduction in plasma TG. After 5 years follow-up, a 26% 
reduction in the secondary endpoints were observed, namely cardiovascular death, MI 
and stroke (51).  
Matsuura et al. (51) analysed a large number of studies proving an inverse correlation 
between HDL and CV disease risk. This study revealed that, whereas small HDL particles 
were the most effective lipoproteins removing cholesterol, large HDL particles had the 
highest capacity of containing cholesterol. Furthermore, they also demonstrated that 
the function of both small and large HDL are altered in patients with ACS, suggesting 
that new strategies to rise HDL efflux capacity should be considered besides to increase 
its levels (51). Cholesteryl ester transfer protein (CEPT) is a protein that transfers the 
cholesteryl ester group from HDL to VLDL, chylomicrons, and their remnants, decreasing 
concentrations of the first while increasing concentrations of the last. Anacetrapib is a 
CEPT inhibitor, which leads to LDL depletion and the formation of larger HDL particles 
with increased content of cholesteryl ester (59).  
Statin treatment generally do not diminish Lp(a) levels, making them a potential CV 
disease risk factor. Recent studies suggested that Lp(a) levels <50 mg/dL have beneficial 
impact on CV disease risk reduction, and this might be achieved with PCSK9 inhibitors, 
apo(a) antisense oligonucleotides or the CETP inhibitor anacetrapib (51). Furthermore, 
elevated levels in patients with chronic renal insufficiency proved to be related with 








1. Statins are currently established as the leading treatment for primary and 
secondary prevention of AMI. High-dose statin treatment can reach up to a 55% 
LDL levels reduction, achieving LDL levels goal, but it is associated with only a 30% 
risk reduction in CV events and a 23% reduction in mortality of CV disease and non-
fatal MI. 
2. The current alternatives for patients intolerant to high-dose statin treatment are 
cholesterol absorption inhibitors, PCSK9 inhibitors and bile acid sequestrants, 
which also demonstrated to have improvements in CV risk reduction when added 
on top of the basal statin treatment.  
3. Combined therapy of statins with ezetimibe, a cholesterol absorption inhibitor, has 
shown 22-26% LDL levels reductions beyond statins monotherapy, with an 
additional 2% absolute risk reduction in CV events. 
4. Monotherapy with the mAbs alirocumab or evolocumab inhibiting PCSK9 have 
shown average LDL reductions by 60%. It has been related with a 12% risk reduction 
in primary endpoint risk, and further reductions up to 19% over time. Clinical trials 
have shown up to 27% reductions in MI risk, but there were no observed reductions 
in cardiovascular death rates. Contrarily, combined therapy with statins can reach 
up to a 40 to 70% LDL levels reduction, related with a 20% reduction in mortality 
rates. 
5. Bile acid sequestrants monotherapy has shown an 18 to 25% reduction in LDL 
levels, reflected in an average 19% reduction in CHD and nonfatal MI, but all causes 
of death rates were not significantly reduced. Combined therapy with statins 
reflected an additional 10-16% reduction in LDL levels when compared with satin 
monotherapy. There are no data about the effects of the combined therapy on 
mortality rates, but it seems reasonable to deduce that it will induce comparable 
reductions in mortality. 
6. Beyond LDL levels reduction, many patients still remain at high risk of having a CV 
event because of the residual risk, which includes high TG rich lipoprotein and Lp(a) 




7. Fibrates are established as the leading treatment for those patients with residual 
risk. Fibrates decrease plasma TG by a 30% and increase plasma HDL levels about 
9% in patients with mixed dyslipidaemia and high TG baseline levels, which 
reflected a 22% reduced odd of nonfatal MI. These figures are even improved when 
fibrates are combined with statin treatment. 
8. Until now, combined therapy with a lipid-lowering drug on top of statin treatment 
has helped improve outcomes, but results show that further improvements are 
needed. The recent discovery of monoclonal antibodies as lipid-lowering therapy 
is showing promising results in CV events risk reduction. New research focused on 
this approach should be developed to obtain more information about the 
antibodies safety and the benefits-cost relation. 
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